Weight gain associated with integrase inhibitor-based treatment has become a critical issue in the clinical management of HIV infection. We analyzed changes in weight and body fat mass in 54 virologically suppressed patients who switched to lamivudine plus raltegravir or dolutegravir. Overall, after 12 months we reported a not significant increase in weight (median, +1.74 kg; p = .223) and total fat mass (median, +1.13 kg; p = .188), and these changes were comparable between groups. The median change in lumbar spine bone mineral density (BMD) [interquartile range (IQR)] was +0.02 g/cm² (−0.02, +0.05; p = .786), and the median change in femur neck BMD (IQR) was +0.04 g/cm² (−0.03, +0.06; p = .598), and changes were comparable between groups. In conclusion, the switch to dolutegravir/lamivudine or raltegravir/lamivudine dual therapy in virologically suppressed patients did not produce significant increases in weight and body fat mass after a 12-month follow-up, in association with not significant changes in BMD.

中文翻译：

---

简短交流：改用拉米夫定加多替拉韦或拉特拉韦双重组合的 HIV 感染者的体重和体脂质量没有显着变化

与基于整合酶抑制剂的治疗相关的体重增加已成为 HIV 感染临床管理中的一个关键问题。我们分析了 54 名改用拉米夫定加拉替拉韦或多替拉韦的病毒学抑制患者的体重和体脂量变化。总体而言，12 个月后，我们报告体重（中位数，+1.74 kg；p  = .223）和总脂肪量（中位数，+1.13 kg；p  = .188）没有显着增加，并且这些变化在组间具有可比性。腰椎骨矿物质密度 (BMD) [四分位距 (IQR)] 的中位数变化为 +0.02 g/cm ² (-0.02,  +0.05 ; p = .786)，股骨颈 BMD (IQR) 的中位数变化为 +0.04 g/cm ² (-0.03, +0.06; p = .598），并且各组之间的变化具有可比性。总之，在 12 个月的随访后，病毒学抑制患者改用多替拉韦/拉米夫定或拉特拉韦/拉米夫定双重治疗不会导致体重和体脂量显着增加，而 BMD 没有显着变化。